Processing your payment...
Please do not close your browser.

Anti-Asthmatics and COPD Drugs Market - Global Growth, Trends and Forecast (2022 - 2027) By Types, By Application, By Regions, and By Key Players: Novartis AG (SWX: NOVN), Merck & Co (NYSE: MRK), GlaxoSmithKline (LON: GSK), Roche (SWX: ROG)

31 May, 2022 | 112 Pages
Shares
facebook sharing button
linkedin sharing button
twitter sharing button
sharethis sharing button

Registering a CAGR of 4.7% over the forecast period, the market value of Anti-Asthmatics and COPD Drugs is expected to reach US$ 96,436.2 million in the year 2027.



Anti-Asthmatics and COPD Drugs Market Overview



Physical examination and tests such as X-rays, sputum eosinophils, and nitric oxide tests can be used to diagnose asthma and COPD. Inhaled corticosteroids, leukotriene modifiers, and theophylline can be used to treat asthma and COPD. Acute respiratory attacks, on the other hand, can be controlled with short-acting beta-agonists and anticholinergic drugs.



Increased prevalence of respiratory diseases, increased incidence of tobacco smoking, global warming, geriatric population, emerging markets, new methods for drug discovery, and an increase in healthcare expenditure are all growth factors in the historical period. Patent expiration and political uncertainty stifled the market.



Future growth in the anti-asthmatics and COPD drugs market will be driven by the increased popularity of e-cigarettes/vaping, rising obesity levels, technology, a large pool of undiagnosed population, use of anti-asthmatics and COPD drugs to treat COVID-19 patients, and increased consumption of fats. Future market growth may be hampered by side effects associated with respiratory drugs, a reduction in free trade, and stringent regulations.



The report aspects discussed the profile of the top manufacturers of the global Anti-Asthmatics and COPD Drugs market. These aspects include the financial status of major companies, trending advancements, and the entire market scenario. Growth of the report has examined Anti-Asthmatics and COPD Drugs Market production, demand and growth potential, geographic analysis, as well as current market developments in various regions and countries.



Who are the Major Players in the Anti-Asthmatics and COPD Drugs Market?



The global Anti-Asthmatics and COPD Drugs include the identification and analysis of the various market participants competing in the global market. Prominent competitors include Novartis AG (SWX: NOVN), Merck & Co (NYSE: MRK), GlaxoSmithKline (LON: GSK), Boehringer Ingelheim Gmbh, AstraZeneca (LON: AZN), Roche (SWX: ROG), Teva Pharmaceutical, Vectura, Pfizer, Abbott, Mylan, Allergan, Cipla, Glenmark Pharmaceuticals, Akorn and others.



Industry News and Updates:



Glenmark introduces Tavulus® for COPD treatment in Spain, making the company one of the first to introduce a bioequivalent version of the dry powder inhaler.



11 October 2021: Glenmark Pharmaceuticals Limited, a global integrated pharmaceutical company focused on research, today announced the launch of a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) in Spain under the brand name Tavulus® for the treatment of chronic obstructive pulmonary disease (COPD).





What are the major Applications, Types, and Regions of the Anti-Asthmatics and COPD Drugs Market?



The market is segmented based on the type, applications, companies, and regions.



By Type, it is segmented into




  • Bronchodilators

  • Anti-inflammatory Drugs

  • Monoclonal Antibodies

  • Combination Drugs



By Application, it is segmented into




  • Asthma

  • Chronic Obstructive Pulmonary Disease



Anti-Asthmatics and COPD Drugs Market Regional Analysis



During the forecast period, the North American region is expected to dominate asthma and COPD drugs market. This expansion can be attributed to the increasing prevalence of diseases such as COPD and asthma, the aging population, increased R&D activities, and the presence of key market players.




  • North America


    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East & Africa

    • Latin America





The Anti-Asthmatics and COPD Drugs Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type, and segment. It focuses extensively on revealing a detailed regional analysis. The Global Anti-Asthmatics and COPD Drugs Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.



What is our Anti-Asthmatics and COPD Drugs Market report scope?



Scope of the Report covers the Anti-Asthmatics and COPD Drugs Market with a detailed analysis of the overall scenario for the market. It also highlights the business participants’ environment in the global marketplace. This report also provides an overview of leading companies covering the latest successful marketing strategies, market contributions, current and historical background, and latest market happenings to help key organizations to grow and generate larger profits. Business players will greatly benefit from this Anti-Asthmatics and COPD Drugs Market analysis report as it has vital details to provide about regional markets and expected opportunities for the prediction time period 2022-2027. Growth between segments is used to understand the different growth factors that are expected to dominate the market as a whole and to develop strategies to differentiate between key applications and target markets. It further reveals how the worldwide market is working through efficient information graphics.



























































Report Attributes



Report Details



Report Title



Anti-Asthmatics and COPD Drugs Market - Global Growth, Trends and Forecast (2022 - 2027) By Types, By Application, By Regions, and By Key Players: Novartis AG (SWX: NOVN), Merck & Co (NYSE: MRK), GlaxoSmithKline (LON: GSK), Roche (SWX: ROG)



Forecast Period 2022 to 2027 CAGR



CAGR of 4.7% over the forecast period (2022-2027)



By Type




  • Bronchodilators

  • Anti-inflammatory Drugs

  • Monoclonal Antibodies

  • Combination Drugs



By Application




  • Asthma

  • Chronic Obstructive Pulmonary Disease



By Companies



Novartis AG, Merck & Co, GlaxoSmithKline, Boehringer Ingelheim Gmbh, AstraZeneca, Roche, Teva Pharmaceutical, Vectura, Pfizer, Abbott, Mylan, Allergan, Cipla, Akorn



Regions Covered




  • North America

  • Europe

  • Asia-Pacific

  • Rest of the World



Countries Covered




  • US

  • Canada

  • Germany

  • France

  • UK

  • Italy

  • Spain

  • Rest of Europe

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific

  • Middle East & Africa

  • Latin America



Base Year



2022



Historical Year



2017 to 2021



Forecast Year



2022 to 2027



Number of Pages



112



Customization Available



Yes, the report can be customized as per your needs




 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



Key Takeaways from this Anti-Asthmatics and COPD Drugs Report




  • Evaluate Anti-Asthmatics and COPD Drugs market potential through analyzing growth rates (CAGR %), Volume (Units), and Value ($M) data given at the country level - for product types, end-use applications, and different industries verticals.

  • Understand the different dynamics influencing the market - growth driving factors, specific challenges, and hidden opportunities.

  • Get in-depth insights on your competitor’s performance – revenue, shares, business strategies, financial benchmarking, product benchmarking, SWOT analysis, and more.

  • Analyze the sales and distribution channels across geographies to enhance top-line revenues.

  • Understand the demanding supply chain with a deep dive on the value augmentation at each, in order to optimize value and bring efficiencies to your processes.

  • Get a quick outlook on the Anti-Asthmatics and COPD Drugs market entropy – M&As, deals, partnerships, and product launches of all key players for the past 5 years.

  • Evaluate the import-export statistics, supply-demand, and competitive landscape for more than the top 20 countries globally for the market.



Frequently Asked Questions



What is the study period of this market?





The Anti-Asthmatics and COPD Drugs Market is studied from 2017 - 2027.



What is the growth rate of the Anti-Asthmatics and COPD Drugs Market?





The Anti-Asthmatics and COPD Drugs Market is growing at a CAGR of 4.7% over the next 5 years.



Who are the key players in Anti-Asthmatics and COPD Drugs Market?



Novartis AG, Merck & Co, GlaxoSmithKline, Boehringer Ingelheim Gmbh, AstraZeneca, Roche, Teva Pharmaceutical, Vectura, Pfizer, Abbott, Mylan, Allergan, Cipla, Akorn



What regions does this Anti-Asthmatics and COPD Drugs Market report cover?





North America (the United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, and Italy)

Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

South America (Brazil, Argentina, Colombia, etc.)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)



What are the significant types of Anti-Asthmatics and COPD Drugs Market?



Bronchodilators, Anti-inflammatory Drugs, Monoclonal Antibodies, Combination Drugs



What are the major end-use applications of Anti-Asthmatics and COPD Drugs Market?



Asthma, Chronic Obstructive Pulmonary Disease              

 



All our reports are custom made to your company’s needs to a certain extent, we do provide 5 free consulting hours along with the purchase of each report, and this will allow you to request any additional data to customize the report to your needs.


  1. INTRODUCTION

    1. MARKET DEFINITION

    2. MARKET DYNAMICS

    3. MARKET SEGMENTATION

    4. REPORT TIMELINES

    5. KEY STAKEHOLDERS



  2. RESEARCH METHODOLOGY

    1. DATA MINING

      1. SECONDARY RESEARCH

      2. PRIMARY RESEARCH

      3. SUBJECT MATTER EXPERT ADVICE



    2. QUALITY CHECK

    3. FINAL REVIEW

      1. DATA TRIANGULATION

      2. BOTTOM-UP APPROACH

      3. TOP-DOWN APPROACH



    4. RESEARCH FLOW



  3. EXECUTIVE SUMMARY

    1. INTRODUCTION

    2. GLOBAL ANTI-ASTHMATICS AND COPD DRUGS MARKET BY APPLICATION

    3. GLOBAL ANTI-ASTHMATICS AND COPD DRUGS MARKET BY TYPES



  4. MARKET DYNAMICS

    1. DRIVERS

    2. INCREASING DEMAND FOR ANTI-ASTHMATICS AND COPD DRUGS RESTRAINTS

      1. STRINGENT ENVIRONMENTAL REGULATIONS

      2. HIGH COST OF RAW MATERIAL



    3. OPPORTUNITIES

      1. ANTI-ASTHMATICS AND COPD DRUGS GROWTH

      2. APPLICATION OF ANTI-ASTHMATICS AND COPD DRUGS



    4. IMPACT OF COVID 19



  5. GLOBAL ANTI-ASTHMATICS AND COPD DRUGS MARKET, BY TYPES

    1. INTRODUCTION

    2. BRONCHODILATORS

    3. ANTI-INFLAMMATORY DRUGS

    4. MONOCLONAL ANTIBODIES

    5. COMBINATION DRUGS



  6. GLOBAL ANTI-ASTHMATICS AND COPD DRUGS MARKET, BY APPLICATION

    1. INTRODUCTION

    2. ASTHMA

    3. CHRONIC OBSTRUCTIVE PULMONARY DISEASE



  7. GLOBAL ANTI-ASTHMATICS AND COPD DRUGS MARKET, BY REGION

    1. NORTH AMERICA

      1. US

      2. CANADA

      3. MEXICO



    2. EUROPE

      1. GERMANY

      2. FRANCE

      3. UK

      4. ITALY

      5. RUSSIA

      6. REST OF EUROPE



    3. APAC

      1. CHINA

      2. SOUTH KOREA

      3. JAPAN

      4. INDIA

      5. AUSTRALIA

      6. ASIAN

      7. REST OF APAC



    4. MIDDLE EAST & AFRICA

      1. SAUDI ARABIA

      2. UAE

      3. SOUTH AFRICA

      4. TURKEY

      5. REST OF MEA



    5. SOUTH AMERICA

      1. BRAZIL

      2. REST OF MEA

      3. ARGENTINA

      4. REST OF SOUTH AMERICA





  8. COMPETITIVE LANDSCAPE

    1. MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,

    2. AND AGREEMENTS

      1. KEY DEVELOPMENT



    3. MARKET SHARE (%) **/RANKING ANALYSIS

    4. STRATEGIES ADOPTED BY LEADING PLAYERS



  9. COMPANY PROFILES

    1. BUSINESS OVERVIEW

    2. COMPANY SNAPSHOT

    3. PRODUCT BENCHMARKING

    4. STRATEGIC INITIATIVES

      1. NOVARTIS AG

      2. MERCK & CO

      3. GLAXOSMITHKLINE

      4. BOEHRINGER INGELHEIM GMBH

      5. ASTRAZENECA

      6. ROCHE

      7. TEVA PHARMACEUTICAL

      8. VECTURA

      9. PFIZER

      10. ABBOTT

      11. MYLAN

      12. ALLERGAN

      13. CIPLA

      14. AKORN





SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

  • Single User License
    $2500
  • Site License
    $3000
  • Global License
    $5000

How can we help you?

Reach us with your research requirements and we shall provide the optimum solution to suit your needs.

Curioust about Multiple Reports?

Discounts available for multiple report purchases.

Contact Us

Our Clients

  • 3M
  • Merck
  • IBM
  • Dow
  • Henkel
  • AirBus
  • Cummins
  • Intel
  • Sony